The cell surface proteoglycans syndecan-1 and -4 interact with laminin 332 to participate in keratinocyte migration. Results: Syndecan-1 and -4 bind specific residues in the laminin 332 LG45 domain.
domains, each containing about 200 residues (LG1-5) (11) . A potential function for the tandem LG4-LG5 domains (LG45) was initially suspected based on the ability of LN332 to trigger distinct cellular events depending on the level of processing of its ␣3 chain. A form of LN332 that lacked the LG45 was found in mature BMs, where it was shown to play an important function in the maintenance of anchoring structures through integrin interactions (12) (13) (14) . In contrast, LN332 with an intact LG45 was found in migratory/remodeling situations such as epidermal repair (15) (16) (17) (18) . Recently, full-length LN332 (with LG45) was proposed to be involved in the invasion of squamous cell carcinomas in vivo (19) .
The mechanism underlying the function of the LG45 domain in LN332 remains poorly understood. Several heparin binding domains (HBD) were identified in the LG45 domain of the ␣3 chain (␣3LG45). These HBDs conferred heparin-dependent cell adhesion properties, which suggested that this region in LN332 could interact with an HSPG cellular receptor (20 -22) . Later, a motif in the LG45 domain that included residues 1412 NSFMALYLSKGR was shown to induce syndecan-2-and -4-mediated cell adhesion, neurite outgrowth, and matrix metalloproteinase-1 and -9 secretion (23) (24) (25) (26) . Further work suggested that this peptide motif also induced keratinocyte migration by triggering syndecan-4 clustering and subsequent ␤1 integrin activation (27) . Others have reported that syndecan-1 was the cellular receptor involved in cell adhesion to the ␣3LG45 domain through its HS and CS chains (28, 29) . This interaction could drive keratinocyte migration by inducing the formation of actin-based cellular protrusions and recruiting syntenin-1 (30, 31) . The first heparin/syndecan-binding sites on LN332 were identified by peptide screening; however, a more recent study identified three novel HBDs based on crosslinking the native protein to heparin beads (22) .
We wondered whether syndecan-1 and -4 interacted with a unique or multiple sequences in the LN332 LG45 domain. To address this question, we aimed to identify residues involved in the interaction between cells and the ␣3LG45 domain and to determine the molecular basis of the syndecan-1 and -4 interaction. By site-directed mutagenesis, we have identified the syndecan-1-and -4-binding sites in the ␣3LG45 domain and have demonstrated that these domains belong to a unique HBD. We further showed that these two receptors bound specifically to overlapping but independent sites through different mechanisms, in addition to the GAGs chains, as the core protein participates in syndecan-4 binding.
EXPERIMENTAL PROCEDURES
Cells and Antibodies-Fibrosarcoma HT1080 cells (CCL-212, American Type Culture Collection) were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 2 mM glutamine and 10% fetal calf serum. Normal human keratinocytes (NHK) cultures were established from foreskin in KBM-2 medium (Cambrex Bio-Sciences, Emerainville, Belgium) as described previously (9) . The human keratinocyte cell line HaCat was grown in 50% Ham's F-12 and 50% DMEM supplemented with 2 mM glutamine and 10% fetal calf serum. The polyclonal antibody (pAb) against syndecan-1 was obtained by rabbit immunization with the GST-syn-1 fusion protein (31); the rabbit pAb H-174 against syndecan-1 was purchased from Santa Cruz Biotechnology (Le Perray en Yvelines, France); the rabbit pAb S9111-60 against syndecan-4 was purchased from US Biologicals (distributed by Euromedex, Mundolsheim, France), and the anti-HS F58-10E4 was from Seikagaku (distributed by AMS Biotechnology, Oxfordshire, UK). The pAb against the LG45 fragment was described elsewhere (29) .
Plasmids and Transfection-The human laminin ␣3LG45 domain (nucleotides 4057-5142) was generated by RT-PCR amplification of poly(A) ϩ mRNA isolated from NHK with the following primers: 5Ј-GAATTCGAATTCGCTAGCTTGCT-CACCACTTCCCAAGACCCAGGCC and 5Ј-TCTAGATCT-AGATGCGGCCGCCTGGTCAGGACAACCATTCAGACT-GAC. The resulting PCR product of 1080 bp was restrictiondigested with NotI and NheI and inserted in-frame with sequences that encoded the BM-40 signal peptide and the sixhistidine tag in the mammalian expression vector pCEP-Pu (32) . Site-directed mutagenesis was performed on the LG45 sequence to substitute the lysine and arginine residues (single, double, or triple, as indicated in Fig. 1 ) to glutamine. This was accomplished by PCR amplification with oligonucleotides that contained the mutation sequences. The mutated PCR products were cloned into pCEP-Pu. All inserts and borders were fully sequenced (Genome Express, Meylan, France). These vectors were stably transfected into 293-EBNA cells (Invitrogen) with the FuGENE 6 reagent (Roche Diagnostics). Transfected cells were selected with 0.5 g/ml puromycin and grown to confluence. Conditioned medium samples from transfected and wild type cells were analyzed with SDS-PAGE to confirm the secretion of WT and mutated recombinant LG45-His 6 fusion peptides into the medium.
Fusion proteins between GST and the human syndecan-1 and -4 ectodomains (GST-hS1ED and GST-hS4ED, respectively) were produced as followed. To append the ectodomain of syndecan-1 (Gln-18 to Gln-232) and syndecan-4 (Glu-19 to Phe-141) to the C terminus of GST, the cDNA encoding these domains was amplified by PCR, subcloned into EcoRI and NotI sites of pGEX-4T3 (GE Healthcare), and sequenced. GST fusion proteins were then produced in bacteria and purified on glutathione-Sepharose 4B beads (GE Healthcare) or 96-well glutathione-chelate plates (Nunc, Dutscher, Brumath, France) as recommended by the manufacturer's instructions.
Purification and Heparin Binding Assay for Recombinant
LG45 Fragments-The recombinant LG45 proteins were secreted by transfected 293-EBNA cells cultured in serum-free DMEM. The conditioned medium was collected every 48 h, and 50 M N-ethylmaleimide and 50 M phenylmethanesulfonyl fluoride were added. To purify the His 6 -tagged LG45 proteins, conditioned medium was mixed with imidazole (10 mM) and salt (0.3 M NaCl) and applied to 5-ml nickel/nitrilotriacetic acid columns (Ni-NTA Superflow Cartridge, Qiagen, Coutaboeuf, France). After washing with 50 mM NaH 2 PO 4 , 300 mM NaCl, 20 mM imidazole, proteins were eluted with a linear gradient of 20 -400 mM imidazole. SDS-PAGE analysis showed an estimated protein purity of Ͼ90%. Protein concentration was determined with the bicinchoninic acid assay (Pierce). To evaluate protein affinity for heparin, LG45-His 6 proteins were placed in a 1-ml HiTrap heparin column (GE Healthcare) in 0.02 M Tris-HCl, pH 7.4, followed by elution with a linear gradient of 0 -1 M NaCl. All the collected fractions were further analyzed by SDS-PAGE followed by Coomassie staining.
Cell Adhesion Assays-LG45 peptides were immobilized on multiwell nickel-chelate plates (Nunc). To ensure equal amounts and identical orientations of all immobilized proteins, multiwell plates were coated with serial dilutions of LG45 substrates in 0.01 M KCl and allowed to adsorb overnight at 4°C. Plates were washed with PBS and saturated with 1% BSA. Next, HT1080 cells were prepared by detaching with 5 mM EDTA/ PBS, followed by rinsing and suspending in serum-free medium; cells were seeded on LG45-coated plates at 8 ϫ 10 4 cells/ well. After 30 min, nonadherent cells were removed with a PBS wash. The extent of adhesion was determined by fixing adherent cells and then staining with 0.1% crystal violet and measuring absorbance at 570 nm as described previously (33 (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 250 M phenylmethylsulfonyl fluoride, 1 mM N-ethylmaleimide, 1% Nonidet P-40, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS). All the following procedures were performed at 4°C. After centrifugation, lysate protein concentrations were determined, and equivalent amounts of proteins were tested in either ELISAbased syndecan-1 and -4 binding assays or affinity precipitation experiments. The ELISA-based assay was performed with 96-well nickel-chelate plates, coated with WT or mutated LG45-His 6 , as described above. After plates were saturated with 1% BSA for 4 h at 4°C, cell lysates were added (300 g/well) and incubated overnight at 4°C. After washes with lysis buffer and PBS, plates were incubated for 3 h with anti-syndecan-1 or antisyndecan-4 pAbs. The plates were then washed with PBS and incubated with appropriate FITC-conjugated secondary antibodies (Jackson ImmunoResearch) for 1 h. After PBS washes, 50 l of 20 mM NH 4 OH with Triton 0.5% was added to each well, and fluorescence intensity was determined at 485-535 nm with a VICTOR X4 Technologies reader (PerkinElmer Life Sciences). A blank value corresponding to BSA-coated wells was systematically subtracted, and each assay point was derived from triplicate measurements. In case of pretreatment with heparitinase I, cells were incubated in digestion buffer (20 mM sodium acetate, pH 7.0, 5 mM CaCl 2 ) with or without 8 milliunits/ml heparitinase I (Seikagaku America, Coger, Paris, France) for 4 h at 25°C prior to the lysis in RIPA buffer.
For syndecan-1 and -4 pulldown experiments, 100 g of WT or mutated LG45-His 6 proteins were linked to nickel magnetic beads (Millipore SAS, Molsheim, France) for 2 h at 4°C in incubation buffer (50 mM NaH 2 PO 4 , pH 8, 300 mM NaCl). Next, beads were washed in incubation buffer, followed by incubation with 1 mg of cell lysis extract, supplemented with 10 mM imidazole for 2 h. Beads were then washed in lysis buffer with 20 mM imidazole and incubated in digestion buffer with 8 milliunits/ml heparitinase I and 50 milliunits/ml chondroitinase ABC for 2 h at 25°C. Proteins were resolved on 8 or 10% SDSpolyacrylamide gels. Separated proteins were transferred to nitrocellulose, followed by immunodetection of syndecan-1 or syndecan-4 by enhanced chemiluminescence.
GST-syndecan-1 and -4 ectodomains were immobilized on multiwell glutathione-chelate plates (Nunc). The wells were blocked with 4% milk in PBS and incubated with soluble LG45 (10 g/ml) for 4 h at 22°C. They were further exposed (1 h, 22°C) to a constant amount of anti-LG45 pAb, and detection was performed using FITC-conjugated antibodies as described above.
Circular Dichroism (CD) Spectroscopy-CD spectra were recorded on an Aviv Model 215 instrument (Aviv Biomedical Inc., Lakewood, NJ; 1-nm bandwidth, 0.2-nm steps, 3-5 s per point accumulation time) equipped with a thermostatted cell holder. Buffer baselines were recorded in the same cell and subtracted. Data were smoothed and normalized to mean residue ellipticities [⌰] MRW . Samples were dialyzed into 200 mM NaF, 20 mM NaH 2 PO 4 /NaOH, pH 7.2. Full spectra (260 to ϳ180 nm; dynode voltage Ͻ500 V) were collected at protein concentrations of ϳ0.5 mg/ml in a 0.02-cm quartz cuvette at 4°C. Concentrations were determined by absorption at 280 nm, assuming an extinction coefficient of ⑀ 280 ϭ 25,940 M Ϫ1 cm Ϫ1 , based on the amino acid composition (35) . CD spectra were deconvoluted to determine secondary structure content with the CDsstr algorithm (36) , as implemented in the Dichroweb server (37) with the reference data sets SP175 (190 -260 nm) (38) and 3 (185-260 nm) (39) . Thermal transition curves were constructed from spectra recorded in a 0.1-cm cell (protein concentration ϳ0.1 mg/ml) at various temperatures between 4 and 85°C upon stepwise heating. Ellipticities [⌰] observed at 200, 207, and 218 nm as a function of temperature were normalized to the fraction of folded protein, Surface Plasmon Resonance (SPR)-based Binding AssayReal time binding analyses were performed on a Biacore 3000 apparatus, operated by a Biacore 3000 control software 4.1 version (Biacore Sweden). HS (average mass ϭ 15 kDa; Celsus Laboratories; Cincinnati, OH) was biotinylated at the reducing end, as described previously (41), and immobilized on a CM4 Biacore sensorchip. Briefly, two flow cells were activated with 50 l of 0.2 M N-ethyl-NЈ-(diethylaminopropyl)-carbodiimide and 0.05 M N-hydroxysuccinimide. Next, 50 l of streptavidin (Sigma) at 0.2 mg/ml in 10 mM sodium acetate buffer, pH 4.2, was injected. The remaining activated groups were blocked with 50 l of 1 M ethanolamine, pH 8.5. Typically, this procedure allowed coupling of ϳ2500 response units of streptavidin on both flow cells. Biotinylated HS (15 g/ml) was then injected over one surface (until achieving a level of 50 response units), and the other surface remained untreated to serve as a negative control. Before use, the chip was submitted to several injections of 2 M NaCl and washed in a continuous flow of 10 mM Hepes, pH 7.4, 0.15 M NaCl, 0.05% P20 detergent. For binding assays, WT or mutant ␣3LG45 was injected over both negative control and HS surfaces for 5 min at 25°C at a rate of 50 l/min. The HS surface was regenerated with a 1-min pulse of 0.05% SDS followed by a 2-min pulse of 2 M NaCl. Apparent dissociation constants were estimated by fitting the steady state values at equilibrium R eq (c) assuming one or two binding sites with
Molecular Modeling-A three-dimensional model of the ␣3LG45 domain pair was generated with ProMod II (Version 3.70 SP3 (42)). The x-ray derived coordinates of mouse LN ␣1
LG45 (Protein Data Bank code 2JD4, chain B (43)) served as a template. After optimizing the alignment manually, a final total energy of Ϫ7025 kJ/mol was achieved.
RESULTS

Production and Purification of Recombinant ␣3LG45-His 6
Proteins-The ␣3LG45 fragment was produced as described previously (29) except that a His 6 tag was added at the C terminus. Transfected human embryonic kidney 293-EBNA cells secreted LG45-His 6 protein into the culture medium. We tested the effect of the His 6 tag on the ability of recombinant LG45-His 6 to bind heparin. As shown in Fig. 1A , the protein was captured on heparin-Sepharose beads and was released with 1 M NaCl buffer. Purification was based on His 6 tag binding to Ni-NTA-conjugated beads, followed by elution with an imidazole buffer. SDS-PAGE analysis of untagged and His 6 -tagged LG45 proteins revealed a slight difference in the migration of the two proteins (Fig. 1B) .
To test whether specific arginine and lysine residues in the ␣3LG45 domains are involved in heparin and syndecan binding (Fig. 1C) , we substituted these charged residues with glutamine. The side chain volume and hydrophilicity are more closely related to the basic residues than the alanine typically used in substitution studies (43) (44) (45) (46) . First, we designed a series of single or double mutant proteins (Fig. 1D, mutants 1-12 ). Then we designed a second series that included triple mutants (mutants [13] [14] [15] [16] [17] [18] . Residues were selected based on sequence alignments among homologous human LN isoforms. We mutated all residues that were shown to participate in heparin binding in the ␣1 chains (43, 44) and ␣4 chains (46) . Residues Lys-1387 and Arg-1389 were mutated (mutant 1), because the corresponding residues in the ␣1 and ␣2 chains have been shown to be involved in syndecan-1 binding (47). Lys-1421 (mutant 4) and Arg-1423 (mutant 5) were mutated because these residues have previously been shown to affect heparin and cell binding based on a synthetic peptide approach (24) , although the Lys-1421 residue is substituted with acidic residues in the mouse and rat ␣3 chains. Double and triple mutant proteins 13 and 14 cover simultaneous mutations of the lysine residues within the synthetic peptide A3G75aR reported as responsible for syndecan-2-and -4-mediated cell binding activity (23) . Finally, Arg-1436, Lys-1438, Lys-1497, and Lys-1613 (located in LG5), were mutated because these were identified as heparin-binding residues in a study where native ␣3LG45 was cross-linked to heparin beads, and the sequences involved were characterized (22) . WT LG45 and all mutated LG45 proteins were expressed in 293-EBNA cells and secreted into the culture medium. They were purified using Ni 2ϩ -chelated beads. Each mutated protein migrated as a major band, displayed a molecular mass equivalent to that of WT, and gave a strong signal when probed in immunoblots with the anti-LG45 pAb (Fig. 1D) .
␣3LG45 and Mutant Protein Binding to Heparin and HSThe binding properties of WT and mutated LG45 were tested on a heparin Hitrap column. We started with low ionic strength to determine the NaCl concentrations required for displacement ( Table 1) . As the His 6 tag did not affect the heparin binding properties of LG45, this system was suitable for testing the properties of mutant LG45 proteins. The analysis of proteins 1-14, including single, double, and triple mutants (Fig. 1D) , revealed that two proteins carrying a single mutation (Arg-1436 or Lys-1438) eluted from the column at a much lower ionic strength (0.48 M NaCl) than the WT ␣3LG45 (0.65 M NaCl). This suggested that this sequence might harbor a major binding site. Four mutants behaved identically to the WT protein, but six other mutants eluted at 0.6 M NaCl suggesting that additional residues may also participate, to a lesser extent, in GAG interactions. Combining mutations of two or three of these low binding residues (mutants 13 and 14, Fig. 1D ) only slightly modified the ionic strength to 0.55 M NaCl. Therefore, a series of double and triple mutants was designed to target the sequence 1433 KKLRIKSKEK, which harbors residues Arg-1436 and Lys-1438 (Fig. 1D, lower panel) . These mutants displayed severe defects in heparin binding. When both the Arg-1436 and Lys-1438 residues were mutated, the defect in heparin binding was only moderately intensified, 0.44 M NaCl being necessary for elution. When a neighboring residue, Lys-1434, was mutated, the mutant protein eluted at 0.54 M NaCl. When all three residues were combined, Lys-1434/Arg-1436/Lys-1438, the mutant eluted at a NaCl concentration of only 0.41 M. In contrast, another combination mutant, Arg-1436/Lys-1438/ Lys-1440, eluted at the same NaCl concentration required for eluting the Arg-1436/Lys-1438 mutant. These data suggest that the residues Lys-1434, Arg-1436, and Lys-1438 were critical for heparin binding of the LG45 domain. As the binding to heparin was not fully abolished with any of the mutated LG45 proteins, we used SPR spectroscopy to analyze the WT and mutated LG45 interactions with HS. First, we determined the affinity of WT LG45 for HS using biotinylated HS immobilized on a streptavidin-coated sensor chip. This system mimicked to some extent cell membrane-anchored HSPG. We injected a range of concentrations (8.7-100 nM) of LG45 to measure binding ( Fig. 2A) . The association phase (from 150 to 450 s) was allowed to proceed to equilibrium. Both the association and dissociation (t Ͼ 450 s) kinetics indicate a complex interaction mechanism with a fast phase followed by a slower one, which is especially obvious by the long time required to reach base-line levels after protein injection stopped. This behavior probably reflects the heterogeneity of the HS preparation with respect to length and sulfation pattern. To reduce bias in deriving affinity data from rate constants, we focused on establishing steady state values at equilibrium. R eq as a function of protein concentration was fitted assuming one or two binding sites resulting in high affinity dissociation constants of ϳ10 and ϳ6 nM, respectively, indicating that WT LG45 displayed a strong affinity for HS (Fig. 2B) .
The same assay was used to determine the HS binding strength of the different LG45 mutants (Fig. 2C) . We injected WT or mutant LG45 proteins (all at 13 nM) over the HS surface. The binding responses of the mutants were compared with that of WT LG45. The binding to HS was slightly different as compared with that observed with heparin (Fig. 2C) . Although only two mutated LG45s showed affinity equivalent to the WT, sev- eral mutants showed a 20 -35% affinity decrease. Among these, K1411Q, K1421Q, and R1423Q mutants displayed equivalent binding to HS even when they were combined. In contrast with the heparin binding studies, the Lys-1440/Lys-1442 mutant showed a 50% decrease in binding to HS. The three Lys-1434, Arg-1436, and Lys-1438 mutants each displayed an equivalent 60% binding that dropped to 10% when mutated Arg-1436 and Lys-1438 were combined confirming the importance of these residues. The two triple mutants, Lys-1434/Arg-1436/Lys-1438 and Arg-1436/Lys-1438/Lys-1440, failed to bind to HS, confirming that LG45 encompasses a unique major site for HS binding.
Structure and Stability of ␣3LG45 and Mutant Proteins-To ensure that mutations did not impact on heparin binding through incorrect protein folding, all protein variants were analyzed by CD spectroscopy. Far-UV CD spectra were recorded for wild type ␣3LG45 and all mutant fragments (Fig. 3A) . Within the 260 to 190-nm range, all spectra were identical within experimental error. No significant changes were observed between 4 and 45°C. The spectra showed a characteristic minimum at 218 nm and maxima at 201 and 189 nm, which was consistent with data reported for the proteolytically derived fragment E3 from mouse tumor laminin-111 that comprised the ␣1LG45 domains (48) . Deconvolution of the spectra showed that the ␣-helix and ␤-strand contents were 2-4 and 40 -44%, respectively. This agreed with the 1.2% ␣-helix and 46.9% ␤-sheet contents found for the x-ray-derived structure of the mouse ␣1LG45 domain pair (Protein Data Bank code 2JD4, see Ref. 43 ). When heated above 45°C, the CD signal indicated unfolding of the LG45 domains (Fig. 3B) , which was not reversible upon cooling. Assuming a two-state transition, data fitting resulted in apparent melting temperatures between 57.5 and 59.2°C. The CD spectra and the thermal stability indicated that ␣3LG45 and all mutant proteins had very similar conformations consistent with the x-ray-derived structures of laminin LG domains (43, 45, 49) .
␣3LG45 and Mutant Protein Binding to Syndecan-1 and -4-We previously showed that cell adhesion to the ␣3LG45 fragment relies on the HSPG receptor syndecan-1 without involvement of syndecan-4 (29, 30). In several cell types, including NHK and HT1080 cells, the syndecan-1 receptor induced, in an integrin-independent manner, the formation of filopodiumlike protrusions (29 -31) . We therefore used this model to investigate whether the various mutations could affect the syndecan-1 interaction. Cell adhesion assays were performed with HT1080 cells as these cells are more easily dissociated from culture plates with EDTA. We found that the different heparin affinities of ␣3LG45 proteins correlated well with syndecan-1-mediated cell adhesion. HT1080 cells displayed similar adhesion when placed on WT LG45 and all mutant LG45 proteins that required either 0.65, 0.6, or 0.55 M NaCl concentrations for elution from heparin (Fig. 4A) . Only cell adhesion to the Arg-1436 and Lys-1438 mutants (0.48 M NaCl) was decreased. The analysis of cell phenotypes (Fig. 4B ) revealed that cells plated on all mutants, except Arg-1436 and Lys-1438 mutants, spread and formed protrusions in a manner comparable with cells plated on the WT protein (60 -70% of adhered HT1080 cells developed microspikes). The cells plated on Arg-1436 and Lys-1438 mutants failed to form protrusions (only 2% of adhered cells developed protrusions) and were clustered in aggregates. We then performed a dose-response analysis of cell adhesion to the mutants that targeted the sequence 1433 KKLRIKSKEK (Fig.  4C) . This confirmed that Lys-1434, Arg-1436, and Lys-1438 were crucial for syndecan-1-mediated cell adhesion, and protrusion elongation required residues Arg-1436 or Lys-1438. Indeed, the single Lys-1434 mutant displayed reduced cell adhesion, equivalent to that observed with the Arg-1436 and Lys-1438 mutants, but Lys-1434 also formed protrusions. Cells failed to adhere to the Lys-1434/Arg-1436/Lys-1438 triple mutant at all concentrations tested. Moderate but equivalent adhesion was obtained with either the Arg-1436/Lys-1438 or Arg-1436/Lys-438/Lys-1440 mutants. This suggests that the Lys-1440 residue mutation did not affect -mediated cell adhesion.
As other studies have shown that syndecan-4 can interact with ␣3LG45 (23, 24), we investigated whether syndecan-1 and -4 extracted from cell lysates can interact with LG45 through the same binding site. First, we used solid phase assays to test WT and mutated LG45 proteins immobilized on nickel-chelate plates with solubilized syndecan-1 and -4 derived from human keratinocyte (HaCat) cells that express significant amounts of syndecan-1 and -4 (Table 1) (29) . The first series of mutants (mutants 1-14, Fig. 1 ) revealed that both Arg-1436 and Lys-1438 mutants displayed a 20 -30% reduced affinity for syndecan-1 and -4. In contrast, all the other mutants were comparable with WT LG45 in binding syndecan-1 and -4. Unexpectedly, the Lys-1440/Lys-1442 mutant was deficient in syndecan-4 binding as a residual 20% interaction could be detected. The second series of mutants (mutants 15-18, Fig. 1 ) revealed that syndecan-1 failed to bind the Lys-1434/Arg-1436/Lys-1438 mutant, which confirmed our syndecan-1-mediated HT1080 cell adhesion data. Interestingly, syndecan-4 moderately interacted with the Lys-1434/Arg-1436/Lys-1438 mutant, but failed to bind to the Arg-1436/Lys-1438/Lys-1440 mutant. These results suggest that, although Lys-1440 was apparently not essential for syndecan-1 binding, it was critical for syndecan-4 binding. We tested this hypothesis by affinity precipitation (pulldown) experiments (Fig. 5, A and B) . HaCat cell lysates were mixed with nickel magnetic beads coated with WT or mutated LG45 proteins. Beads were subjected to heparitinase/ chondroitinase ABC treatment, and gel sample buffer was added to the samples prior to their electrophoresis analysis so that all bound syndecan-1 and -4 could be detected. Western blot analysis revealed bands that corresponded to syndecan-1 or syndecan-4 ( Fig. 5A ) core proteins in the material bound to the WT and mutant LG45 proteins. Consistent with the solid phase assays, the Arg-1436/Lys-1438 mutant showed important defects in both syndecan-1 and syndecan-4 binding; syndecan-1 failed to interact with the Lys-1434/Arg-1436/Lys-1438 mutant, whereas syndecan-4 failed to bind the Arg-1436/ Lys-1438/Lys-1440 mutant. The experiment was repeated using NHK and HT1080 cells (Fig. 5B) with the most relevant mutated LG45 proteins and produced similar results. These results show that syndecan-1 and syndecan-4 share a common FIGURE 3. CD spectra and thermal stability of ␣3LG45 WT and mutant proteins. A, far-UV CD spectra were recorded at 4°C for the protein samples (numbers indicated on the right correspond to those shown in Fig. 1D ). Spectra were staggered by successive addition of ϩ500 degrees cm 2 dmol
Ϫ1
, i.e. the signal at ϳ260 nm is around zero for all proteins. B, thermal transition curves were derived from full spectra. Data points represent the mean values of the degree of folded protein F, as defined under "Experimental Procedures," observed at 200, 207, and 218 nm. Lines represent fits assuming a two-state transition. To facilitate comparisons, data are staggered by ϩ0.2 units.
binding site that includes residues Arg-1436 and Lys-1438 in LG45.
Syndecan-4 Binding to LG45 Involves Both HS and the Core Protein-The
LG45/syndecan-1 interaction was previously shown to rely exclusively on GAGs with a participation of both HS and CS (29) . To study the mechanism of syndecan-4/LG45 binding, intact as well as HS-free GAGs from cells were compared to reveal the role of HS in syndecan-4 binding (Fig. 5C ). NHK and HT1080 cells were either untreated or treated with heparitinase I to degrade HS. WT and mutated LG45 proteins immobilized on nickel-chelate plates were incubated with solubilized intact or enzyme-treated cell lysates, and bound syndecan-4 was detected by ELISA. Treatment of the cells with heparitinase I only partially prevented interaction of the syndecan-4 with LG45 suggesting another binding mechanism.
Although HS digest only moderately decreased syndecan-4 interaction with the tested mutants, it completely abrogated the residual interaction observed with the Lys-1440/Lys-1442 mutant. As shown in Fig. 5C (right panel) , heparitinase I digest was efficient as HS were not detected in the heparitinase I-treated lysates. To further evaluate the binding of the syndecan-1 and -4 core proteins to LG45, we produced fusion proteins between GST and the human syndecan-1 and -4 ectodomains (GST-hS1ED and GST-hS4ED respectively). The fusion proteins were purified on glutathione-Sepharose beads and analyzed by SDS-PAGE followed by Coomassie Blue staining (Fig. 5D) . The GST-hS1ED and GST-hS4ED were then immobilized on glutathione plates and tested for their ability to interact with soluble LG45 protein. As shown in Fig. 5D, LG45 was detected only in wells coated with GST-hS4ED reinforcing the hypothesis that the syndecan-4 core protein participates in the binding to LG45.
Effect of WT and Mutant
LG45 on Keratinocyte Migration-A study reported that LG45 could stimulate NHK migration when added to the culture through a mechanism involving syndecan-4 (26, 27 ). Therefore, we tested whether mutation in the syndecan-4-binding site could affect this phenomenon. We directly assessed the migratory behavior of NHKs by monitoring cell migration for 8 h with a time-lapse video recorder. The individual cell tracks (Fig. 6A ) showed marked differences in behavior when WT ␣3LG45 was absent or present in the culture medium. Maximal relative distances to the origin measurements revealed that 80% of cells plated in the absence of LG45 covered distances less than 50 m; in contrast, 65% of cells plated with WT LG45 covered 50 -200 m (n ϭ 100 cells, p Ͻ 0.001; Fig. 6B) . Interestingly, the mutant protein deficient in syndecan-4 binding (Arg-1436/Lys-1438/Lys-1440) failed to trigger NHK motility. These results confirm previous findings showing that soluble LG45 stimulate NHK migration and further show that residues Arg-1436/Lys-1438/Lys-1440 are involved in this phenomenon.
DISCUSSION
Unique HS Binding Domain within ␣3LG45 Harbors Specific Syndecan-1-and -4-binding Sites-This study demonstrates
that the ␣3LG45 domain of LN332 harbors a major HS binding region ( 1433 KKLRIKSKEK) that was different from any sequences previously identified through synthetic peptide screening (20, 23, 50) . Thus, in this case, short peptides could not reproduce the structural conformation assumed by this region within the full-length protein. Interestingly, the sequence identified in this study was identical to one of the three HBDs identified by Vivès et al. (22) . We performed a more detailed analysis, which revealed that three critical residues (Lys-1434, Arg-1436, and Lys-1438) were involved in syndecan-1 interaction. In addition, we found that syndecan-4 could bind a region in LG45 that was different from that recognized by syndecan-1. A mutant encompassing residues Lys-1440 and Lys-1442 displayed major defects in syndecan-4 interaction suggesting an important role for this region, and we suggest that this region may encompass the syndecan-4 core protein binding domain. We further showed that Arg-1436, Lys-1438, and Lys-1440 are the key residues involved in the syndecan-4 interaction. Taken together, our results show that syndecan-1 and syndecan-4 bind to distinct but overlapping sites, with a common region including residues Arg-1436 and Lys-1438. Each site contains additional specific residues located N-or C-terminal to these two central residues.
Specific residues involved in heparin, dystroglycan, syndecan, and calcium binding have been identified by site-directed mutagenesis for the LG4 or LG45 domains of the laminin ␣1, ␣2, and ␣4 chains and corroborated by x-ray structural analysis for ␣1 and ␣2 (43) (44) (45) (46) . Our results show that the cluster of basic residues (Lys-1434 to Lys-1438) in ␣3LG4 that were responsible for heparin and syndecan-1 and -4 binding (Table 1) correspond to similar clusters identified in the ␣1 and ␣4 chains (Fig.  7A) . The ␣2 chain has no basic residues within this sequence region. Instead, the ␣2LG5, rather than the ␣2LG4, domain appears to be responsible for heparin binding (49, 51) . Lysine and arginine residues are also found in the equivalent positions of the ␣3 chains of mouse, rat, chicken, and frog (Xenopus tropicalis). Mutations of Lys-1440 and Lys-1442 had no significant effect on the binding to heparin or syndecan-1 but led to markedly reduced binding to syndecan-4 ( Table 1 ). The ␣4LG4 lysine residue, which corresponds to Lys-1442 (Fig. 7A) , was partially involved in heparin binding, but the mutant was not tested for syndecan interactions (see Table 1 in 46). For known ␣3 chains, including rat, mouse, chicken, and frog, residues in the position equivalent to Lys-1442, but not Lys-1440, are either lysine or arginine, which indicates potential functional importance.
Syndecan-1 and -4 Binding Domains Are Juxtaposed and Both Accessible-A homology-based structural model of the human ␣3LG45 domains with the mouse ␣1LG45 crystal structure as a template (43) showed that the residues involved in heparin binding were located on the outer edge of ␤-strand G (see nomenclature accompanying Ref. 49) , although residues involved in syndecan-4 binding were within the adjacent loop that connects strands G and H (Fig. 7B) . Strand G forms the outer edge of the concave ␤-sheet of the ␤-sandwich structure. We identified an additional group of mutants that also contributed to heparin binding as they were eluted at 0.6 M NaCl. SPR analysis of the interactions between these mutants and HS confirmed these findings and identified Arg-1402, Lys-1411, Lys-1421, Arg-1423, and Lys-1497 as low GAG affinity residues. The structural model suggests that the concave surface of the ␤-sheet might act as a groove to align GAG chains along low affinity residues and direct them toward Arg-1436 and Lys-1438. A surface view of this structure (Fig. 7C) shows that the NH 2 groups of the basic residues involved in heparin and syndecan binding are accessible.
In addition to site-directed mutagenesis studies of the LN LG domains (43) (44) (45) (46) 49) , short synthetic peptide studies have elucidated heparin-and syndecan-binding sites. Peptide A3G75aR, which harbored residues 1412 NSFMALYLSKGR of human ␣3LG45, was found to bind to heparin and promote cell adhesion through syndecan-2 and -4 (23). Another report described a heparin-binding synthetic peptide 1399 KPRLQF-SLDIQT of the mouse ␣3LG4 sequence corresponding to residues 1387-1398 of human ␣3LG4 (Fig. 1C) (20) . We made mutant ␣3LG45 proteins that had substitutions of Lys-1387/ Arg-1389, Lys-1421, or Arg-1423 with glutamine; however, these showed no effects on syndecan-1 or -4 binding (Table 1 and Fig. 5 ). Similar discrepancies between alternative approaches were also found for HBDs within the LG domains of the ␣1, ␣2, and ␣4 LN chains (cf. Fig. 7A with Fig. 7 of Ref. 52 ). This probably indicates that binding required a specific spatial arrangement of the functional amino acid side chains, which cannot be adopted within a short peptide.
This study reveals that the GAG chains of syndecan-1 and -4 expressed by NHK interact with specific residues in LG45. It shows that residues Arg-1436/Lys-1438 participate in both syndecan-1 and -4 binding, although residues Lys-1434 and Lys-1440 are specific for binding to syndecan-1 and -4, respectively. This is the first study to demonstrate this type of specificity in syndecan binding in any LN or other ECM protein. It has long been suspected that specific sulfation patterns are required for specific HS/ligand interactions, and the overall structure of the HS was reported to be of importance (53) . We have not investigated whether the specificity observed depends on the GAG compositions or their sulfation levels in this study. Future analysis will be carried out to determine the molecular basis of the glycosaminoglycan interaction specificity. In addition, our data showing binding of the syndecan-4 core protein to the laminin ␣3LG45 are novel. This interaction is likely to contribute to the syndecan-4-specific interaction. These findings corroborate previous studies showing the involvement of the core protein in syndecan-4 interaction and function (54, 55) .
Specific Syndecan-1 and -4 Interactions with ␣3LG45 May Trigger Specific Cellular Responses-Numerous studies have indicated that the LG45 domain of the human LN332 ␣3 chain plays an important role in controlling cellular behavior, and it is believed to interact with HSPG cellular receptors, either in an immobilized or soluble manner. In normal conditions, after secretion and deposition in the BM, LN332 rapidly undergoes specific processing, including the cleavage of its LG45 domain. This cleavage allows the first three LG1-3 domains to bind integrins and support biological activities in epithelial BMs (33, 56, 57) . Some studies have revealed that the LG45 domain can function both in the full-length LN332 molecule and after it is processed and released. When syndecan-1 was allowed to interact with immobilized LG45 either alone or within pre-LN332, it induced the formation of protrusive adhesion structures through activation of Rac and Cdc42 GTPases (30) . Our cell adhesion experiments revealed that Lys-1434, Arg-1436, and Lys-1438 residues are required for syndecan-1-mediated cell adhesion and Arg-1436 or Lys-1438 for protrusion elongation (Fig. 4) . We previously showed that syndecan-4 is not involved in this mechanism (30), and we confirmed here that residues specific for the syndecan-4 interaction (Lys-1440/ Lys-1442) were not involved in syndecan-1-mediated cell adhesion. Other in vitro studies reported that adding either recombinant ␣3LG45 or LG4 to the culture medium could induce migration of NHK (26) . It was further suggested that this migration depended on a specific sequence within LG4 ( 1412 NSFMALYL-SKGR; see Ref. 23) . We have confirmed that the WT LG45 domain induces keratinocyte motility, and we have shown that this property is dependent on the syndecan-4 binding domain. These results reinforce previous data that LG45 had a specific syndecan-4-dependent mobilizing effect (27) . In contrast to that study attributing the effect to 1412 NSFMALYLSKGR based on synthetic peptides, we found that in native ␣3LG45, this property is carried by residues 1436 RIKSKEK. . Sequence/structure relation of amino acid residues that interact with heparin and syndecans. A, human LN ␣3LG4 sequence (residues 1362-1534) was aligned to that of mouse LN ␣1LG4 (residues 2718 -2898; accession number P19137), LN ␣2LG4 (residues 2755-2934; accession number Q60675), and LN ␣4LG4 (residues 1457-1636; accession number P97927).
Residues that diminished heparin binding activity when mutated to glutamine (␣3) or alanine (␣1, ␣2, and ␣4), are shown in white on a black background. Other basic residues that could be mutated with no significant effect on heparin binding are shown in bold and underlined. Residues in the ␣3 chain that affected syndecan-4, but not heparin binding, are highlighted in green.
Aspartic acid residues involved in Ca 2ϩ binding are highlighted in purple. All cysteine residues are highlighted in yellow. Mutation data were reproduced from previous studies for the ␣1 (43, 44), ␣2 (45), and ␣4 chains (46) . The assignment to ␤-strands A-N (boxed), using the nomenclature of Tisi et al. In this study, we have identified syndecan-1-and -4-binding sites in the ␣3LG45 domain of LN332. Our results provide the first evidence that specific residues in ␣3LG45 interact with each of these syndecans. Several lines of evidence have suggested that LG45 is connected to LN332 in the ECM during wound repair (12, 16, 58, 59 ). LG45 in full-length LN332 was shown to play a central role in the polarization and migration of cells (18, 60) and syndecan-1 binding to LG45 was shown to support keratinocyte migration over immobilized full-length LN332 (29, 30) . Moreover, the LG45 region has also been demonstrated to function in the deposition and/or retention of fulllength LN332 in the ECM (19, 61, 62) . The identification of the syndecan-1-and -4-binding sites in the LN332 LG45 domain is a first step toward understanding of the function of these syndecans in keratinocyte biology.
